Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. / Zastrozhin, Michael S.; Skryabin, Valentin Y.; Torrado, Marco; Petrovna, Anastasiya; Sorokin, Alexander S.; Grishina, Elena A.; Ryzhikova, Kristina A.; Bedina, Inessa A.; Buzik, Oleg Z.; Chumakov, Egor M.; Savchenko, Ludmila M.; Brun, Evgeny A.; Sychev, Dmitry A.
в: Pharmacogenomics, Том 21, № 2, 01.2020, стр. 111-123.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder
AU - Zastrozhin, Michael S.
AU - Skryabin, Valentin Y.
AU - Torrado, Marco
AU - Petrovna, Anastasiya
AU - Sorokin, Alexander S.
AU - Grishina, Elena A.
AU - Ryzhikova, Kristina A.
AU - Bedina, Inessa A.
AU - Buzik, Oleg Z.
AU - Chumakov, Egor M.
AU - Savchenko, Ludmila M.
AU - Brun, Evgeny A.
AU - Sychev, Dmitry A.
PY - 2020/1
Y1 - 2020/1
N2 - Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-Time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.
AB - Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-Time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.
KW - alcohol addiction
KW - anxiety disorders
KW - benzodiazepines
KW - biotransformation
KW - bromodihydrochlorobenzodiazepine
KW - personalized medicine
KW - phenazepam
KW - Anxiety Disorders/drug therapy
KW - Anti-Anxiety Agents/administration & dosage
KW - Humans
KW - Genotype
KW - Male
KW - Benzodiazepines/administration & dosage
KW - Adult
KW - Cytochrome P-450 CYP2C19/genetics
KW - Female
KW - Alcoholism/genetics
KW - SUBSTANCE-ABUSE
KW - CYP2C19
KW - MOOD
KW - CYP2D6
KW - MIDAZOLAM
KW - DEPRESSION
KW - GENETIC POLYMORPHISMS
KW - HALOPERIDOL
KW - BENZODIAZEPINES
KW - RESPONSES
KW - bromodihydrochloroben-zodiazepine
UR - http://www.scopus.com/inward/record.url?scp=85077990650&partnerID=8YFLogxK
UR - http://www.mendeley.com/catalogue/effects-cyp2c192-polymorphisms-efficacy-safety-phenazepam-patients-anxiety-disorder-comorbid-alcohol
UR - https://www.mendeley.com/catalogue/c91a33d2-b26d-362d-a5a9-8883489d99d6/
U2 - 10.2217/pgs-2019-0019
DO - 10.2217/pgs-2019-0019
M3 - Article
C2 - 31957548
AN - SCOPUS:85077990650
VL - 21
SP - 111
EP - 123
JO - Pharmacogenomics
JF - Pharmacogenomics
SN - 1462-2416
IS - 2
ER -
ID: 50738937